骨肉瘤多组学研究进展
Research Progress on Multi-Omics Research in Osteosarcoma
王磊鑫 1孙承军1
作者信息
- 1. 武汉科技大学附属华润武钢总医院,湖北武汉 430080
- 折叠
摘要
骨肉瘤(osteosarcoma,OS)是最常见的原发性恶性骨肿瘤,具有高侵袭性和转移性.随着高通量测序技术的发展,组学综合分析在临床应用上变得更为便捷,为多种肿瘤治疗提供了新途径.在OS中,丰富的转录组学、基因组学、表观遗传学、蛋白质组学数据提供了基因表达、基因突变、化学修饰等宝贵信息,有助于更深入地了解OS的分子机制和生物学特征.此外,新兴的单细胞测序能在单细胞水平上定量分析基因表达,揭示不同细胞类型的分子特征,比较OS细胞差异,甚至探究OS的起源等.回顾目前基因组学、转录组学、表观遗传学、蛋白质组学以及新兴的单细胞组学在OS上的研究进展,有助于更全面了解OS发生、进展机制,同时有望发现潜在的治疗靶点,为OS的临床治疗提供重要指导和启示.
Abstract
Osteosarcoma(OS)is the most common primary malignant bone tumor with highly inva-sive and metastatic properties.With the development of high-throughput sequencing technology,comprehensive omics analysis has been applied clinically,providing new ways for the treatment of various tumors.Abundant data of transcriptome,genome,epigenetic and proteomics provide valu-able information related to gene expression,gene mutations and chemical modifications of OS,deepening our understanding its molecular mechanisms and biological characteristics.In addition,emerging single-cell sequencing can quantify gene expression at the cell level,reveal the molecu-lar characteristics of different cell types,compare cell differences,and even explore the origin of OS.This paper reviews the the current progress of multi-omics research in OS to provide infor-mation and inspiration for the clinical treatment of OS.
关键词
骨肉瘤/基因组学/转录组学/表观遗传学/单细胞测序/治疗靶点Key words
osteosarcoma/genomes/transcriptome/epigenetic/scRNA-seq/therapeutic target引用本文复制引用
出版年
2024
NETL
NSTL
万方数据